Share on facebook Share on Twitter Share on Google Plus Share This

Cardiovascular Disease

There are many different forms of cardiovascular (heart) disease.  The most common cause of cardiovascular disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself.  This is called coronary artery disease and happens slowly over time.  Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure.  Some people are born with cardiovascular disease.

Programs + Services


CardioVascular Center

Learn about the Cardiovascular Center at Tufts Medical Center, providing heart transplants and other treatments for patients with cardiac disease.
More information about programs and services


Hypertrophic Cardiomyopathy Center

Explore the Hypertrophic Cardiomyopathy (HCM) Center at Tufts Medical Center in Boston which offers a full suite of cardiomyopathy treatment and diagnostic options.
More information about programs and services


Changing the narrative on a once grim genetic cardiac disease

Cardiovascular specialists at Tufts MC are spreading the word that Hypertrophic Cardiomyopathy (HCM) is now a treatable disease compatible with normal longevity and good quality of life.
More information about programs and services

Doctors + Care Team

Mark D. Iafrati, MD

Mark D. Iafrati, MD

Title(s): Chief, Vascular Surgery; Director, Vascular Center; Director, Center for Vascular, Wound Healing and Hyperbaric Medicine; Vascular Surgeon; Associate Professor, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Vascular Surgery
Appt. Phone: 617-636-5019
Fax #: 617-636-8003

Complex vascular surgery, vascular biology, endovascular surgery, venous surgery, complex wound care

View Full Profile

Hanna Ahmed, MD, MPH

Hanna Ahmed, MD, MPH

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-5913

Clinical cardiology, cardiovascular imaging

View Full Profile

Research + Clinical Trials


A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.
More information about research and clinical trials


HeartMate PHP™ Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 60 sites in the US. Control device will be the Abiomed Impella® Recover® LP 2.5 Percutaneous Cardiac Support System.

Additionally, the study will include a nonrandomized roll-in phase at each site. Each site must first enroll and treat up to 3 patients in the nonrandomized roll-in phase before entering the randomized phase.

Assess the safety and efficacy of the HeartMate PHP in supporting patients with severe symptomatic coronary artery disease with diminished but stable cardiovascular function, who are undergoing elective or urgent high risk percutaneous coronary interventions (PCI) but are not candidates for coronary artery bypass graft (CABG) surgery.

Proposed Indications The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent,

hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.  Nonrandomized Roll-In Phase: Up to 180 patients undergoing PCI per the Inclusion/Exclusion criteria; up to 3 roll-in patients per site.

Randomized Phase: Up to 425 patients undergoing PCI per the Inclusion/Exclusion criteria.

Data will be collected at baseline, during the PCI procedure, postprocedure, discharge, and 90 days post device removal.

All patients will have a follow-up visit at 90 days post-device removal.


More information about research and clinical trials


Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial  (TAVR UNLOAD)

The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.

Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis


More information about research and clinical trials


Entrestotm (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

The purpose of this study is to test whether EntrestoTM, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. EntrestoTM has been studied in only a very small number of patients with advanced heart failure, like you. This study is beind done to obtain more information on the benefits and risks of EntrestoTM in patients with advanced heart failure. Both EntrestoTM and valsartan have previously been approved by the U.S. Food and Drug Administration (FDA)for people with heart failurea nd are available by prescription from a licensed medical doctor. Currently EntrestoTM is only available under the brand name EntrestoTM, there is no generic form of EntrestoTM. You do not have to take part in this study in order to receive EntrestoTM.
More information about research and clinical trials


Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (The COAPT)

This is a study to evaluate the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation (FMR) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site’s local heart team as not appropriate for mitral valve surgery. Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (Device group) or to no MitraClip device (Control group). Approximately 610 subjects will be randomized with approximately 305 subjects targeted to receive the study device.
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn’t make you feel small.  At Tufts Medical Center the patient is at the center of everything that we do.  This means we’re committed to providing the highest quality of care in a safe, friendly environment.

Learn more
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history